DEF: Sunshine Biopharma Seeks Shareholder Approval for Equity Plan Expansion

Sunshine Biopharma Inc. will hold its 2025 Annual Meeting to elect directors, ratify auditors, and vote on a significant increase in its equity incentive plan shares.

Summary

• The 2025 Annual Meeting of Shareholders will be held online on December 11, 2025, at 10:00 a.m. Eastern Time, with October 17, 2025, as the record date for voting.
• Shareholders will vote on the election of five directors, including Camille Sebaaly as a new nominee, while current director Dr. Abderrazzak Merzouki will not be up for reelection.
• The appointment of M&K CPAS, PLLC as the independent registered public accountant for the year ending December 31, 2025, is up for ratification, following the dismissal of two previous auditors in 2024 and 2025.
• A key proposal seeks to amend the 2023 Equity Incentive Plan to increase the number of shares authorized for issuance thereunder from 1,661 to 683,000.
• As of October 17, 2025, there were 4,905,945 shares of common stock and 130,000 shares of Series B Preferred Stock outstanding, with each Series B share carrying 1,000 votes.
• Dr. Steve N. Slilaty, CEO, holds all 130,000 Series B Preferred shares, granting him significant voting control.
• The company reported a Total Shareholder Return of (99.9%) in 2024 and a net loss of $(5,134,116) in 2024, which worsened from a $(4,506,044) loss in 2023.
• Executive compensation for Dr. Slilaty increased significantly in 2024 to $1,211,587, largely due to an $800,000 bonus paid to Advanomics Corporation, a company he controls.
• New employment agreements for executive officers, effective January 1, 2024, or January 13, 2025, include substantial severance payments, such as $14 million for Dr. Slilaty if terminated without cause or for good reason.

Sentiment

Score: 2

Explanation: The filing reveals extremely poor financial performance with a near 100% loss in Total Shareholder Return and worsening net losses. Executive compensation increased significantly despite this, and there are concerns regarding auditor changes and potential dilution from a large increase in the equity incentive plan shares. The concentration of voting power with the CEO is also a negative governance factor.

Positives

• The company is actively addressing its auditor situation by appointing M&K CPAS, PLLC, following issues with a previous firm, aiming to ensure compliance and financial reporting integrity.
• The Board of Directors is recommending the approval of the 2023 Equity Incentive Plan amendment, which could help attract and retain key talent through equity awards, a common practice in the biopharma sector.
• The company has established various committees (Audit, Compensation, Nominating and Corporate Governance) with independent directors, indicating a structured approach to corporate oversight.

Negatives

• Total Shareholder Return was a significant negative (99.9%) in 2024, indicating substantial value destruction for common shareholders.
• Net income worsened in 2024, with a loss of $(5,134,116) compared to $(4,506,044) in 2023, signaling ongoing financial challenges.
• Executive compensation, particularly for the CEO, increased substantially in 2024, including an $800,000 bonus paid to a company controlled by the CEO, despite the poor financial performance and negative shareholder return.
• The company has changed its independent registered public accounting firm twice in 2024 and 2025, initially due to SEC charges against its former auditor and then a subsequent dismissal, which could raise concerns about financial reporting stability.
• The proposed increase in authorized shares for the equity incentive plan from 1,661 to 683,000 represents a substantial potential dilution for existing shareholders, especially given the current market capitalization and share price.
• The Audit, Compensation, and Nominating and Corporate Governance Committees did not meet separately in 2024, which could indicate less active oversight by these key governance bodies.

Risks

• The significant negative Total Shareholder Return of (99.9%) in 2024 highlights substantial investment risk and potential for further value erosion.
• The worsening net loss from $(4,506,044) in 2023 to $(5,134,116) in 2024 indicates ongoing financial challenges and operational inefficiencies.
• The substantial increase in authorized shares for the 2023 Equity Incentive Plan to 683,000 could lead to significant dilution for existing common stockholders if these awards are granted.
• The company's reliance on the CEO, Dr. Steve N. Slilaty, who holds 100% of the Series B Preferred Stock with 1,000 votes per share, concentrates voting power and could limit the influence of common shareholders.
• The absence of policies and practices on the timing of equity awards in relation to the disclosure of material nonpublic information could create perceived or actual insider trading risks.
• The company's history of changing independent auditors twice in 2024 and 2025, including one due to SEC charges against the former auditor, could raise red flags regarding financial reporting reliability and internal controls.

Future Outlook

The company aims to attract and retain employees, consultants, and directors who will contribute to its long-range success by expanding its equity incentive plan. Management also anticipates annual salary increases for executive officers based on a minimum of 5% or the US Consumer Price Index, whichever is greater.

Management Comments

• "On behalf of our Board of Directors, I cordially invite you to attend our 2025 Annual Meeting of Stockholders on December 11, 2025, at 10:00 a.m., Eastern Time, which shall be held online." (Dr. Steve N. Slilaty, Chairperson of the Board of Directors)
• "During the meeting we will discuss the items of business described in the accompanying Notice of Annual Meeting and Proxy Statement, update you on important developments in our business and respond to any questions that you may have about us." (Dr. Steve N. Slilaty, Chairperson of the Board of Directors)
• "Our Board believes that Dr. Steve N. Slilaty, our Chief Executive Officer, is best suited to act as Chairman of the Board because he is the director most familiar with the Company’s business and industry and is therefore best able to identify the strategic priorities to be discussed by the Board." (Board of Directors)
• "We believe that there is an insufficient number of shares available under our 2023 Plan to meet our current and projected needs. Accordingly, it is the judgment of our Board that the amendment is in the best interest of the Company and its stockholders." (Board of Directors regarding 2023 Plan Amendment)
• "We believe that the amendment is appropriate to permit the grant of equity awards at expected levels for the future." (Board of Directors regarding 2023 Plan Amendment)

Industry Context

As a biopharma company, Sunshine Biopharma operates in a highly competitive and capital-intensive industry where attracting and retaining top scientific and executive talent is crucial. The proposed expansion of the equity incentive plan is a common strategy in this sector to align employee interests with shareholder value and incentivize long-term performance, especially given the long development cycles and high-risk nature of drug discovery. However, the significant negative shareholder return and worsening net losses indicate that the company is currently underperforming relative to the growth expectations often associated with the biopharma industry, suggesting challenges in its R&D pipeline or commercialization efforts.

Comparison to Industry Standards

• The (99.9%) Total Shareholder Return in 2024 is an extreme outlier compared to typical performance in the biopharma industry, where even significant R&D setbacks or market downturns rarely lead to such a near-total loss of value in a single year. For instance, major biopharma indices or even individual development-stage companies, while volatile, generally do not exhibit this level of value destruction without a catastrophic event like a failed Phase 3 trial or bankruptcy filing.
• The worsening net loss from $(4.5) million in 2023 to $(5.1) million in 2024, coupled with the negative TSR, indicates a lack of operational improvement or successful pipeline advancement, which contrasts with the trajectory of successful biopharma companies that typically show progress towards profitability or significant clinical milestones to justify ongoing losses.
• The substantial executive severance packages (e.g., $14 million for the CEO) are disproportionately high when benchmarked against the company's current market capitalization, financial performance, and the typical compensation structures for executives in early-stage or struggling biopharma firms, where compensation is often more heavily weighted towards performance-based equity tied to specific milestones.
• The rapid succession of auditor changes (BF Borgers, Bush & Associates, M&K CPAS) within a year, especially one initiated by SEC charges against a former auditor, is highly unusual and falls significantly below corporate governance best practices for public companies, which prioritize auditor stability and independence to ensure reliable financial reporting.
• The concentration of 100% of Series B Preferred Stock, carrying 1,000 votes per share, in the hands of the CEO, is a governance structure that deviates from the more dispersed ownership and voting rights typically found in publicly traded companies, potentially limiting the influence of common shareholders and raising concerns about minority shareholder protection.

Management Changes

Corporate Governance

Legal Proceedings

• The SEC settled charges against BF Borgers CPA, PC, the company's former independent registered public accountant, on May 3, 2024, resulting in a permanent ban on appearing or practicing before the SEC. This led to Borgers' dismissal by Sunshine Biopharma.

Related Party Transactions

• On February 8, 2024, the company sold 20,000 shares of Series B Preferred Stock to Dr. Steve N. Slilaty (CEO and Chairman) for a purchase price of $0.10 per share.
• On March 4, 2024, the company sold an additional 100,000 shares of Series B Preferred Stock to Dr. Steve N. Slilaty for a purchase price of $0.10 per share.
• An $800,000 bonus for Dr. Steve N. Slilaty in 2024 was paid to Advanomics Corporation, a company controlled by Dr. Slilaty.
• Dr. Slilaty controls the voting of 1,850 common shares owned by Malek Chamoun, former president of a wholly-owned subsidiary, through a voting agreement dated October 20, 2022.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from the proposed increase in the equity incentive plan shares (from 1,661 to 683,000). Common shareholders experienced a (99.9%) Total Shareholder Return in 2024, indicating substantial value loss. The concentration of voting power with the CEO through Series B Preferred Stock limits common shareholder influence.
• **Employees/Consultants/Directors**: Stand to benefit from the expanded 2023 Equity Incentive Plan, which aims to attract and retain talent through equity awards. Executive officers have new employment agreements with substantial severance packages.
• **Management**: Executive officers have secured new employment agreements with guaranteed annual salary increases and significant severance provisions, providing them with substantial financial security despite the company's poor performance.
• **Regulatory Authorities**: The company's history of auditor changes, including one due to SEC charges against a former auditor, suggests increased scrutiny or potential for future regulatory attention regarding financial reporting.

Next Steps

• Shareholders are to vote on director elections, auditor ratification, and the 2023 Equity Incentive Plan amendment at the Annual Meeting on December 11, 2025.
• The Board will continue to oversee management and strategic direction, with its committees performing their respective duties.
• The Compensation Committee will determine and approve executive officer compensation and make recommendations to the Board regarding compensation plans.
• The Nominating and Corporate Governance Committee will recruit new directors and oversee corporate governance principles.
• Stockholders wishing to submit proposals for the 2026 Annual Meeting must do so by June 25, 2026.

Key Dates

Recommendation

The company exhibits severe financial distress, evidenced by a (99.9%) Total Shareholder Return in 2024 and worsening net losses. Despite this, executive compensation, particularly for the CEO, increased substantially, including a large bonus paid to a controlled entity. The proposed massive increase in the equity incentive plan shares (from 1,661 to 683,000) represents significant potential dilution for common shareholders without clear justification given the current performance and lack of prior grants. Frequent auditor changes raise red flags about financial reporting integrity. The concentration of voting power with the CEO further exacerbates governance concerns. These factors collectively point to a highly unfavorable investment outlook and a strong recommendation to sell.

Keywords

Sunshine Biopharma, SBFM, Proxy Statement, Shareholder Meeting, Equity Incentive Plan, Director Election, Auditor Ratification, Executive Compensation, Corporate Governance, Biopharma, SEC Filing, Stockholder Vote, Dilution, Financial Performance